Literature DB >> 1458287

Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients.

I Lundberg1, U Nyman, I Pettersson, E Hedfors.   

Abstract

Twenty-nine anti-RNP positive patients were followed prospectively with a mean observation time of 65 months (29-120 months). The clinical course was correlated to the presence of IgM and IgG anti-(U1)snRNP antibodies as revealed by immunoblotting from sequentially obtained sera. There was a striking dissociation between the fluctuating course, with the appearance of new manifestations followed by remissions, and the stability of the anti-snRNP antibody specificities where an appearance or a disappearance of anti-snRNP specificities was a rare phenomenon. The main epitope recognized by the IgG antibodies was the 70 kDa protein and of the IgM antibodies the B/B' proteins. No shift from the IgM to the IgG isotype was observed. The presence of IgG anti-70 kDa and IgM anti-B/B' antibodies was highly associated with presence of arthralgias, Raynaud's phenomenon and arthritis. Further, an association was noted between the combined presence of IgG anti-70 kDa, anti-A and anti-C antibodies and IgM anti-B/B' and puffy hands, myositis, pulmonary fibrosis and sclerodactyly, i.e. all manifestations of mixed connective tissue disease (MCTD). On the contrary, serositis as often seen in SLE was correlated to the presence of IgG anti-B/B' antibodies. Thus the longitudinal analysis of the correlation between anti-snRNP antibody specificities and clinical manifestations support the concept of MCTD as a distinct entity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458287     DOI: 10.1093/rheumatology/31.12.811

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  10 in total

1.  Mixed connective tissue disease. A clinico-serological study of 17 cases.

Authors:  I García-de la Torre; M Salazar-Páramo; G Salmón-de la Torre
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

Review 2.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

3.  Enteric Nervous System: Neuropathic Gastrointestinal Motility.

Authors:  Jackie D Wood
Journal:  Dig Dis Sci       Date:  2016-07       Impact factor: 3.199

4.  Blotting patterns of IgG anti-(U1)RNP antibodies in mixed connective tissue disease.

Authors:  A Ghirardello; A Doria; P Vesco; E Vaccaro; C Bernardi; C Catani; U Fagiolo; P F Gambari
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

5.  Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein.

Authors:  M Satoh; J J Langdon; K J Hamilton; H B Richards; D Panka; R A Eisenberg; W H Reeves
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

6.  Follow-up of 151 patients with high-titer U1RNP antibodies.

Authors:  P B Frandsen; N J Kriegbaum; S Ullman; M Høier-Madsen; A Wiik; P Halberg
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

7.  Anti-enteric neuronal antibodies and the irritable bowel syndrome.

Authors:  Jackie D Wood; Sumei Liu; Douglas A Drossman; Yehuda Ringel; William E Whitehead
Journal:  J Neurogastroenterol Motil       Date:  2012-01-16       Impact factor: 4.924

Review 8.  Biomarkers and Autoantibodies of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Authors:  Hajime Yoshifuji
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2016-04-03

9.  Mixed Connective Tissue Disorder Complicated by Polymyositis, Sjogren's Syndrome, Pleural Effusion and Pericarditis.

Authors:  Maryam Kundi; Salman Assad; Sumbal Babar; Usman Ghani; Sahla Hammad; Ahmed G Sheikh; Asif K Kundi; Amjad Sheikh
Journal:  Cureus       Date:  2016-12-01

10.  Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.

Authors:  Z Betteridge; S Tansley; G Shaddick; H Chinoy; R G Cooper; R P New; J B Lilleker; J Vencovsky; L Chazarain; K Danko; M Nagy-Vincze; L Bodoki; M Dastmalchi; L Ekholm; I E Lundberg; N McHugh
Journal:  J Autoimmun       Date:  2019-04-13       Impact factor: 7.094

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.